Interdisziplinäre Therapieempfehlungen zur Behandlung des hormonrefraktären Prostatakarzinoms

Autor:	K. Miller, K. Becker, F. Finke, G. Geiges, B. Göckel-Beining, D. Hossfeld, R. Osieka, C. Rüssel, H. Tesch, L. Weißbach, M. Wirth, J. Wolff
Rok vydání:	2006
Předmět:	Oncology medicine.medical_specialty Chemotherapy Pathology business.industry Urology medicine.medical_treatment Consensus conference medicine.disease Asymptomatic Docetaxel Homogeneous Internal medicine medicine Carcinoma medicine.symptom business Standard therapy medicine.drug
Zdroj:	Aktuelle Urologie. 37:201-204
ISSN:	1438-8820 0001-7868
DOI:	10.1055/s-2006-932205
Popis:	Therapy with Docetaxel for hormone-refractory prostatic carcinoma has for the first time led to an increase in the survival time. Docetaxel has become established as a standard therapy for his indication. Since hormone-refractory prostatic carcinoma is not uniformly defined and is thus for prognosis not a homogeneous entity, the prospects at the start of chemotherapy are uncertain. In the summer of 2005 these questions were addressed in an interdisciplinary consensus conference. It was agreed that the 3-week scheme with 75 mg/m (2) as standard and the indication for symptomatic patients were above question. Opinions differed with regard to the use of chemotherapy in asymptomatic patients. In addition, recommendations for the performance and monitoring of the therapy were formulated.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8dac38e539c09686273891f01ff14bb4 https://doi.org/10.1055/s-2006-932205 Zobrazit plný text záznamu